![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 21, 2016 4:55:19 PM
Biopharm i think you have cut and paste the wrong topic. You almost created AI from PS.
Well I was on the right track and maybe we start seeing the much bigger possibilities with this new knowledge of PS Targeting on just the right "charge"
---------------------------------------------------------
Introduction
The detection and quantification of biomarkers are essential for medical diagnostics, environmental monitoring, and bioresearch. This field has long been dominated by optically based readout techniques utilizing fluorescent markers or those requiring advanced spectroscopic equipment. While other fields have benefited from new technologies based upon advancements in semiconductor integrated circuit technology, chemical and biological sensors have remained dependent upon biochemical assays due to the challenges of achieving sensitivity and selectivity with semiconductor-based sensors. Silicon transistor-based readout sensors have been developed, but these devices suffered from poor sensitivity and selectivity due to fundamental shortcomings of the silicon structure.
Recently, new electronic sensors have overcome the limitations of the current silicon sensors through the development of low dimensional materials, nanowires, nanotubes, and two-dimensional (2D) films. While sensors based upon one-dimensional (1D) structures, specifically carbon nanotubes (CNTs), have demonstrated excellent sensitivity and at least the promise of selectivity, the production of devices from 1D structures has proven difficult. Graphene offers the same performance opportunities as 1D structures along with the advantages of working with a planar film.
Graphene
Graphene, the first 2D atomic crystal material, is a monolayer of carbon arranged in a hexagonal lattice. Andre Geim and Konstantin Novoselov were awarded the Nobel Prize in Physics in 2010 for their groundbreaking experiments on graphene. Graphene has several exceptional material properties particularly well suited for sensor applications, including electrical conductivity.1–3 Ideal mobilities for graphene are estimated to be 200,000 cm2 V–1 s–1.4 Mobilities of 10,000–15,000 cm2 V–1 s–1 have been reported for exfoliated graphene on SiO2-covered silicon wafers,5,6 and upper limits between 40,000–70,000 cm2 V–1 s–1.6,7 Graphene is very stable; it is composed of very short, strong, covalent bonds, all in the plane of the film. The conductivity, stability, uniformity, composition, and 2D nature of graphene make it an excellent material for sensors, overcoming the failings of silicon chemical and biological sensors.
GFET
A graphene field effect transistor (GFET) is composed of a graphene channel between two electrodes with a gate contact to modulate the electronic response of the channel (Figure 1). The graphene is exposed to enable functionalization of the channel surface and binding of receptor molecules to the channel surface. The surface of the GFET channel is functionalized by binding receptor molecules for the specific target of interest.
http://www.sigmaaldrich.com/technical-documents/articles/materials-science/graphene-field-effect-transistors.html
Chemical and Biological Sensing
DNA-Functionalized Carbon Nanotube Chemical Sensors
http://nanophys.seas.upenn.edu/research.html
Like I said at the very, very beginning.... Brigitte Phan (Allergan patent attorney) did not just pop up on the PAV list of the late Dr. Phil Thorpes profile for no reason at all. It took a few years before we finally seen her surface with Donald Bollella(Skywork Solutions..) and Ramon Valencia (Peregrine Pharmaceuticals)
Interesting that she also has Johnson as a client A.T. Charlie Johnson and maybe it certainly was not a coincidence it seemed like she was working with the late Dr. Thorpe...
http://nanophys.seas.upenn.edu/research.html
http://www.plainsite.org/attorneys/allergan-usa-inc/brigitte-phan/
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM